{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:38:31Z","timestamp":1789688311404,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.resinv.2025.04.022","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T18:51:23Z","timestamp":1746730283000},"page":"592-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5878","authenticated-orcid":false,"given":"Toshiyuki","family":"Sumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Ishigooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Koshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.04.022_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.04.022_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JAA.S14520","article-title":"Update on optimal use of omalizumab in management of asthma","volume":"4","author":"Pelaia","year":"2011","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.04.022_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2025.04.022_bib5","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2025.04.022_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.resinv.2025.04.022_bib7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib8","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib9","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.04.022_bib11","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.3390\/jcm12165174","article-title":"Switching to dupilumab from other biologics without a treatment interval in patients with severe asthma: a multi-center retrospective study","volume":"12","author":"Higo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib12","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","article-title":"Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP","volume":"281","author":"Rosso","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.resinv.2025.04.022_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2021.03.015","article-title":"Clinical and economic burden of severe asthma among US patients treated with biologic therapies","volume":"127","author":"Reibman","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resinv.2025.04.022_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.resinv.2025.04.022_bib15","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/ijms22094369","article-title":"Tezepelumab: a potential new biological therapy for severe refractory asthma","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2025.04.022_bib16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (Cascade): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/02770903.2024.2349605","article-title":"Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study","volume":"61","author":"Jim\u00e9nez-G\u00f3mez","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.resinv.2025.04.022_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.alit.2016.12.005","article-title":"Japanese guidelines for adult asthma 2017","volume":"66","author":"Ichinose","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2025.04.022_bib20","unstructured":"https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf."},{"key":"10.1016\/j.resinv.2025.04.022_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.04.022_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.04.022_bib23","unstructured":"Global Iinitiative for asthma (GINA).[accessed February 2, 2024]. https:, http:\/\/ginasthma.org\/wp-content\/uploads\/2023\/07\/GINA-2023-Full-report-23_07_06-WMS.pdf."},{"key":"10.1016\/j.resinv.2025.04.022_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/a-2014-4350","article-title":"Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma \u2013 Der Biologics Asthma Response Score (BARS) [Criteria for evaluation of response to biologics in severe asthma \u2013 The Biologics Asthma Response Score (BARS)]","volume":"77","author":"Milger","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.resinv.2025.04.022_bib25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106793","article-title":"The German severe asthma patient: baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control","volume":"195","author":"Korn","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib27","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.04.022_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with Benralizumab in Spain (ORBE study)","volume":"21","author":"Mart\u00ednez-Morag\u00f3n","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2025.04.022_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/JAA.S311975","article-title":"Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study","volume":"14","author":"Numata","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.04.022_bib30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy","volume":"9","author":"M\u00fcmmler","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.04.022_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.resinv.2024.11.015","article-title":"Molecular mechanisms and clinical impact of biologic therapies in severe asthma","volume":"63","author":"Tashiro","year":"2025","journal-title":"Respir Investig"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:50:31Z","timestamp":1749599431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2212534525000644"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.04.022","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}